|
2022 News Releases
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
LOS ANGELES, Calif., Sept. 6, 2022 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of
Puma, will present an overview of the Company at the hybrid H.C. Wainwright 24 th Annual Global
Investment Conference, which will be held September 12-14, 2022. The virtual presentation will be
available for 30 days beginning at 7:00 a.m. EDT on September 12, 2022 on the Company’s website at
https://www.pumabiotechnology.com.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and
commercialization of innovative products to enhance cancer care. Puma in-licenses the global development
and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant
treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant
trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In
February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the
treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two
or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing
authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients
with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less
than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered
trademark of Puma Biotechnology, Inc.
Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.
Contact:
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
David Schull, Russo Partners, +1 212 845 4200
david.schull@russopartnersllc.com
Olipriya.das@russopartnersllc.com
# # # # #
Back to 2022 News Releases
|
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
|